MX2021007485A - Formulaciones orales de branaplam. - Google Patents
Formulaciones orales de branaplam.Info
- Publication number
- MX2021007485A MX2021007485A MX2021007485A MX2021007485A MX2021007485A MX 2021007485 A MX2021007485 A MX 2021007485A MX 2021007485 A MX2021007485 A MX 2021007485A MX 2021007485 A MX2021007485 A MX 2021007485A MX 2021007485 A MX2021007485 A MX 2021007485A
- Authority
- MX
- Mexico
- Prior art keywords
- branaplam
- oral formulations
- tetramethylpiperidin
- pyridazin
- pyrazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201811048667 | 2018-12-21 | ||
PCT/IB2019/061038 WO2020128915A1 (en) | 2018-12-21 | 2019-12-18 | Oral formulations of branaplam |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021007485A true MX2021007485A (es) | 2021-08-05 |
Family
ID=69165436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021007485A MX2021007485A (es) | 2018-12-21 | 2019-12-18 | Formulaciones orales de branaplam. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220071996A1 (pt) |
EP (1) | EP3897576A1 (pt) |
JP (1) | JP2022513976A (pt) |
KR (1) | KR20210107038A (pt) |
CN (1) | CN113226285A (pt) |
AR (1) | AR117719A1 (pt) |
AU (1) | AU2019404930A1 (pt) |
BR (1) | BR112021011744A2 (pt) |
CA (1) | CA3119084A1 (pt) |
CL (1) | CL2021001621A1 (pt) |
IL (1) | IL283593A (pt) |
MX (1) | MX2021007485A (pt) |
TW (1) | TW202038908A (pt) |
WO (1) | WO2020128915A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202304446A (zh) * | 2021-03-29 | 2023-02-01 | 瑞士商諾華公司 | 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途 |
WO2024015518A1 (en) * | 2022-07-13 | 2024-01-18 | Inaya Therapeutics, Inc. | Inhalable imatinib formulation |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5002935A (en) | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
MY174339A (en) | 2012-08-13 | 2020-04-09 | Novartis Ag | 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions |
-
2019
- 2019-12-18 AU AU2019404930A patent/AU2019404930A1/en not_active Abandoned
- 2019-12-18 EP EP19836564.5A patent/EP3897576A1/en not_active Withdrawn
- 2019-12-18 AR ARP190103731A patent/AR117719A1/es unknown
- 2019-12-18 TW TW108146419A patent/TW202038908A/zh unknown
- 2019-12-18 JP JP2021534722A patent/JP2022513976A/ja active Pending
- 2019-12-18 MX MX2021007485A patent/MX2021007485A/es unknown
- 2019-12-18 KR KR1020217021901A patent/KR20210107038A/ko unknown
- 2019-12-18 BR BR112021011744-0A patent/BR112021011744A2/pt not_active Application Discontinuation
- 2019-12-18 CN CN201980079621.4A patent/CN113226285A/zh active Pending
- 2019-12-18 US US17/415,684 patent/US20220071996A1/en active Pending
- 2019-12-18 CA CA3119084A patent/CA3119084A1/en active Pending
- 2019-12-18 WO PCT/IB2019/061038 patent/WO2020128915A1/en active Application Filing
-
2021
- 2021-05-31 IL IL283593A patent/IL283593A/en unknown
- 2021-06-17 CL CL2021001621A patent/CL2021001621A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2020128915A1 (en) | 2020-06-25 |
CN113226285A (zh) | 2021-08-06 |
TW202038908A (zh) | 2020-11-01 |
IL283593A (en) | 2021-07-29 |
CA3119084A1 (en) | 2020-06-25 |
BR112021011744A2 (pt) | 2021-08-31 |
KR20210107038A (ko) | 2021-08-31 |
CL2021001621A1 (es) | 2022-02-11 |
JP2022513976A (ja) | 2022-02-09 |
EP3897576A1 (en) | 2021-10-27 |
AU2019404930A1 (en) | 2021-06-03 |
US20220071996A1 (en) | 2022-03-10 |
AR117719A1 (es) | 2021-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016010213A (es) | Formulaciones farmaceuticas novedosas. | |
PH12018502438A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
NZ742220A (en) | Pharmaceutical compositions comprising meloxicam | |
PH12019500202A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
AU2018231044A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
PH12019500207A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12019500206A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MY194087A (en) | Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament | |
BR112017027843A2 (pt) | formulações farmacêuticas compreendendo tenofovir e emtricitabina | |
MX2019001322A (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos. | |
PH12020550341A1 (en) | Niraparib formulations | |
MX2018012618A (es) | Composiciones farmaceuticas orales de mesalazina. | |
AR100663A1 (es) | Formulaciones de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona | |
EA202092829A1 (ru) | Композиции тофацитиниба с контролируемым высвобождением | |
WO2019087083A3 (en) | Oral delivery of glp-1 peptide analogs | |
MX2021007485A (es) | Formulaciones orales de branaplam. | |
EP3500291A4 (en) | FORMULATIONS FOR THE ORAL ADMINISTRATION OF ACTIVE AGENTS | |
PH12019500154A1 (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
PH12017501829A1 (en) | Pharmaceutical formulations | |
EP4282414A3 (en) | Modified release tablet formulations containing phosphodiesterase inhibitors | |
IN2013MU01177A (pt) | ||
EA201991286A1 (ru) | Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин | |
EA201890929A1 (ru) | Низкие дозировки композиций дипиридамола для перорального приема и их использование | |
MX2019015869A (es) | Nuevas formulaciones orales de belinostat. |